Capmatinib for cancers with MET gene changes
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system clinical trials.
This study tests an oral drug called capmatinib for people whose cancers have specific changes in the MET gene (except for one type of lung cancer). It aims to see if the drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer has a specific change in the MET gene (like a skip, extra copies, fusion, or mutation) found by a genetic test.
- You have not had a previous treatment that targets the MET pathway, unless your doctor thinks this new drug could still work for you.
- You are willing to have a fresh biopsy (tissue sample) and give blood samples for research.
- Your heart, liver, kidneys, and blood counts are within safe ranges, as checked by lab tests.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether existing cancer medicines can help people whose tumors have specific “gene changes” (mutations). You may be assigned to a treatment arm that matches your tumor’s gene results after fresh biopsy and blood testing.
This trial tests whether tepotinib combined with paclitaxel can treat stomach or gastroesophageal (GEJ) cancer that has spread and has specific MET gene changes. It may help by blocking the MET pathway that can drive tumor growth after standard chemotherapy.
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
This trial tests a targeted treatment given before and after surgery for people with a specific type of early-stage lung cancer that has a BRAF V600 or MET exon 14 mutation. The goal is to see if the treatment helps shrink the tumor before surgery and prevent it from coming back afterward.
This Phase 2 trial tests whether a c-MET inhibitor can slow or shrink advanced solid tumors that have specific c-MET genetic changes. You may be eligible if your cancer has progressed after standard treatment and you meet safety and heart/health requirements.
This study follows people in South Korea who have a specific lung cancer genetic change called “exon 14 skipping” and are going to take Tabrecta (capmatinib). It helps collect real-world safety and results for using this medicine under routine care.
Hear when a new Neoplasms by Histologic Type trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.